Latest Healthcare News

Micro-X Ltd has secured a $5.6 million strategic partnership with Malaysian firm Billion Prima and raised $4 million in capital, marking a pivotal shift towards medical imaging while progressing key security and health technology projects.

Osteopore Limited reported a robust 26% quarter-on-quarter revenue increase in Q1 CY25, bolstered by a key Singapore subsidy listing and a strategic pivot away from its dental project to sharpen commercial focus.

Talius Group reported a solid March quarter with rising revenue, a strategic partnership with Lifestyle SA, and the rollout of its proprietary RTLS software, signaling strong momentum in aged care technology.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Race Oncology has opened a second Australian clinical site for its Phase 1 trial of RC220 combined with doxorubicin in advanced solid tumours, aiming to speed patient enrolment and gather critical safety and efficacy data.

Alcidion Group Limited reported a robust Q3 FY25 with $13.1 million in cash receipts and a landmark 10-year $37.5 million contract with North Cumbria NHS Trust, prompting an upgrade to its full-year EBITDA guidance.

TruScreen has launched a landmark five-year cervical cancer screening program in Ho Chi Minh City, targeting 260,000 women with its AI-driven, non-invasive technology to boost screening rates and support Vietnam’s national health goals.

EBOS Group Limited has announced a fully franked interim dividend of NZD 0.595 per share for the half-year ending December 2024, alongside a Dividend Reinvestment Plan offering a 2.5% discount.

EBOS Group Limited announces the retirement of CEO John Cullity after a decade of strong growth, appointing Adam Hall as his successor to lead the company’s next phase of expansion.

EBOS Group Limited’s interim results for H1 2025 reveal a notable decrease in revenue and profit compared to the prior year, yet the company maintains its interim dividend, signaling confidence despite headwinds.

EBOS Group Limited posted robust interim results for H1 FY25, with underlying EBITDA rising 7.1% excluding the Chemist Warehouse Australia contract, driven by strong organic growth and strategic investments. The company maintained its dividend and reiterated FY25 EBITDA guidance between $575 million and $600 million.

EBOS Group Limited posted a strong half-year performance with underlying EBITDA up 7.1% to $291 million, driven by growth in healthcare and animal care segments, while maintaining its interim dividend amid the loss of the Chemist Warehouse contract.